Marcella Ruddy Biography and Net Worth

Marcie comes to Tectonic with over 15 years of experience in drug development across all stages of clinical development from translational through post approval. Prior to joining our team, she was the Head of the Inflammation and Immunology Clinical Development Group at Regeneron Pharmaceuticals and led the clinical development of Dupixent® through over nine Phase 3 trial initiations and multiple regulatory approvals globally. Over her career, which also has included time at Merck and Alnylam and EMD Serono, she has led and developed teams responsible for clinical programs across a range of therapeutic areas including respiratory, inflammation, bone, anemia and metabolic and rare diseases. Prior to entry into drug development, Marcie held a staff position in the Pulmonary Unit at Massachusetts General Hospital/Harvard Medical School where she founded and directed the Adult Cystic Fibrosis Program. She holds an A.B. from Princeton University and a M.D. from Washington University, St. Louis, and completed her pulmonary critical care fellowship at Harvard Medical School/Brigham and Women’s Hospital in Boston.